C-UGBRmitochondria transplantation, gene therapy, cellular energy metabolism
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Timestamps: 5:00 - The ideal human future 7:27 - Reversing aging vs curing common diseases 10:22 - Longevity tips 13:11 - Societal costs to longevity 20:22 - Recs for 20 year olds About Alexander Schueller & Tobias Reichmuth: Alexander Schueller is the founder and CEO at cellvie, a seed-stage venture developing mitochondria-based therapies. Tobias Reichmuth is a founding partner at maximoon, a venture studio company builder which has already built 2 longevity startups, with 3 more to follow this year. Nowadays we know that there are 9 reasons for human aging, all cell-based: - Genomic instability; - Telomere attrition; - Epigenetic alterations; - Loss of proteostasis; - Deregulated nutrient sensing; - Mitochondrial dysfunction; - Cellular senescence; - Stem cell exhaustion; - Altered inter-cellular comms. Nowadays average life expectancy is at 83. Alexander’s and Tobias’ companies aim not to extend life indefinitely,
Alex Schueller, CEO of cellvie is presenting at the Rejuvenation Startup Summit 2024 Connect to Forever Healthy: * Videos: https://forever-healthy.org/videos/ * News: https://forever-healthy.org/news/ * LinkedIn: https://www.linkedin.com/company/forever-healthy-foundation
Nutze diesen Link https://link.stayoung.de/ForYou_YT und spare mit dem Code: Ruge15 15% Rabatt auf Deine erste Bestellung bei for you ehealth In diesem Podcast spreche ich mit Dr. Alexander Schueller Zusammen mit Wissenschaftlern der Harvard University gründete er das StartUp CellVie, welches die Mitochondrien-Transplantation als Therapie für degenerative Krankheiten erforscht. In dieser Folge besprechen wir: - Wie eine Mitochondrien-Transplantation genau durchgeführt wird. - Wie diese Therapie bei degenerativen Erkrankungen, wie Herzinfarkt, Schlaganfall, Arthrose, Parkinson, Demenz, und vielen weiteren, helfen kann. - Wie diese Therapie schon einigen Babys das Leben retten konnten. - Wie die Therapie auch vorbeugend im Bereich der Healthy Longevity angewendet werden kann. - Welche Risiken die neue Technologie mit sich bringen kann. - Wie weit CellVie in der Erforschung ist und wann wir mit einer Zulassung der Therapie rechnen können. Weitere Informationen zu Dr. Alexande
Born in the US and raised in Switzerland, cellvie is seeking to bring about a new treatment modality: Therapeutic Mitochondria Transplantation, which was conceived at Harvard Medical School. It involves the transfer of viable mitochondria into cells where the energy metabolism has been compromised or is in need of amplification. cellvie is pursuing this technology as a platform, seeking to establish the mitochondria's potential in ischemia-reperfusion injury, gene therapy and aging related degeneration. The first application will be in heart-attack patients, an indication where cellvie's co-founder showed the potential for a 60%-reduction in muscle damage in a corresponding large animal study. If the team succeeds, their work may spur a whole new industry around mitochondria as a category of medicines. cellvie is a 2022 Falling Walls Venture Winner. To learn more about Falling Walls Venture and how you can participate, visit our website: https://falling-walls.com/venture/. Nominate
Alexander Schueller, CEO of cellvie AG at Rejuvenation Startup Summit 2022 Connect to Forever Healthy: * Videos: https://forever-healthy.org/videos/ * News: https://forever-healthy.org/news/ * LinkedIn: https://www.linkedin.com/company/forever-healthy-foundation/
The biotech platform that is leveraging one of the cornerstones of evolution – mitochondria. Mitochondria play a crucial role in the aging process, activating factors and metabolic pathways involved in longevity. Their dysfunction impacts on both lifespan and healthspan, and whilst they have been identified as disease targets for some time, mitochondria have proven difficult to treat. The founders of cellvie wondered if it were possible, as they put it, to leverage one of the cornerstones of evolution – to replace and augment damaged mitochondria. And so, the concept of Therapeutic Mitochondria Transplantation was born. TMT holds the potential of sustainably affecting mitochondria function, and reinvigorating or amplifying the cellular energy metabolism – and having raised $5 million in Kizoo-led seed funding, cellvie is on the way to turning that possibility into a reality. Dr Alex Schueller, Cellvie's CEO, will be speaking at Berlin’s Rejuvenation Startup Summit (14-15 October 20
Click here to listen to the full episode: https://www.swisspreneur.org/podcast/alexander-schueller-tobias-reichmuth-ep253 About Alexander Schueller & Tobias Reichmuth: Alexander Schueller is the founder and CEO at cellvie, a seed-stage venture developing mitochondria-based therapies. Tobias Reichmuth is a founding partner at maximoon, a venture studio company builder which has already built 2 longevity startups, with 3 more to follow this year. Nowadays we know that there are 9 reasons for human aging, all cell-based: - Genomic instability; - Telomere attrition; - Epigenetic alterations; - Loss of proteostasis; - Deregulated nutrient sensing; - Mitochondrial dysfunction; - Cellular senescence; - Stem cell exhaustion; - Altered inter-cellular comms. Nowadays average life expectancy is at 83. Alexander’s and Tobias’ companies aim not to extend life indefinitely, but significantly, and insure quality of life right up until the very end. Longevity companies typically have a hard time
--> Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer | Corporate - EQS News News Feed Events Feed News + Events Feed Recently viewed news Recently viewed events Show all --> Recently viewed Companies Search Results of news Show all Search Results of Companies Show all Search Results of events Show all Watch list Log in Log in E-mail Address Password Remember Me Log in Forgot Password You have not yet registered? Get your account for free. Register Here Back to log in Forgot Password? We will send you a reset link E-mail Re … spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation. Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinso … The investment will enable us to pursue the platform broadly, including a first application in aging, where the need for mitochondria-recovery is particularly dear.” To date, cellvie focused primarily on ischemia-reperfusion injury (IRI), one of the world’s leading causes of death. IRI manifests itself whenever the blood flow to a part of the body is interrupted and subsequently reintroduced. Well-known medical conditions include heart attacks, strokes, and organ … ning research on the root causes of aging into therapies and services for human application. Investments include FoxBio, Turn.bio, AgeX, Elevian, Oisin Biotechnologies, LIfT BioSiences, MAIA Biotechnology, and ohers. Forever Healthy’s other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Agin
cellvie AG - Venture Leaders About Venture Leaders Programs & Destinations 20 Years Success Stories News --> About Venture Leaders Programs & Destinations 20 Years Success Stories News Upcoming 20 pre-clinical studies and an ongoing clinical pilot at Boston Children's Hospital. The technology's initial application will be in ischemia-reperfusion injury, with kidney transplantation as first indication, for which FDA Orphan Drug Designation was obtained. --> Company cellvie AG Incorporated September 2020 Headquarter Zurich Support | Venture Leaders Biotech Biotech From cells to medicine cellvie … ongoing clinical pilot at Boston Children's Hospital. The technology's initial application will be in ischemia-reperfusion injury, with kidney transplantation as first indication, for which FDA Orphan Drug Designation was obtained. Company News Find here the latest news about the company. 31.10.2025 More than 20 Swiss biotech companies to exhibit at Bio Europe (startupticker.ch) 09.09.2025 cellvie secures $5 million to accelerate clinical translation (startupticker.ch) 09.09 … ch innovation on the global stage (venturelab.swiss) 17.06.2021 W. A. de Vigier prize for six startups (startupticker.ch) 12.05.2021 Finalists of the W. A de Vigier revealed (startupticker.ch) 11.03.2021 17 deep-dech start-ups shortlisted for the W.A. de Vigier Award (startupticker.ch) Show all Company Awards Venture Leaders Biotech 2021 Quicklinks About Venture Leaders Upcoming Roadshows Venture Leaders is an exclusive flagship program for Swiss startups, powered by Venturel
Cellvie - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> Cellvie pioneering Therapeutic Mitochondria Transfer, a novel treatment approach aimed at the cellular energy metabolism. Website Profile prev next Website Bookmark Share prev next General Headquarters Houston, Texas, United States Founders & Team Alexander Schueller, James McCully, Pedro del Nido, Sitaram Emani Year Founded 2018 Company type Private company Fu
Meet cellvie founder Alexander Schueller and find out how he leverages the power of evolution through mitochondria therapy About Venture Leaders Programs & Destinations 20 Years Success Stories News --> About Venture Leaders Programs & Destinations 20 Years Success Stories News Upcoming 10 Venture Leaders Biotech 2021 and introduce you to the inaugural graduates of the program. To learn more about the startups, we asked each entrepreneur to complete a short profile and choose at least six questions from a questionnaire about their personal and professional life. Name: Alexander Schueller
Swiss-US biotech secures 5 million USD to advance pipeline News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Capital Repor … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout Swiss-US biotech secures 5 million USD to advance pipeline Financing Please login or register 29.01.2021 Cellvie, a Harvard spin-off founded in the US with headquarters in Zurich, is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company has closed a $5M round to prepare a clinical trial in organ transplantation and to expand … Register for more services Create your personal archive Get the Newsletter Set award alarms Partners Contributors Supporters Supporters News Startup Media House Pinboard News archive Newsletter archive Editorials Directories Awards Grants & Loans Jobs Investors Facts Initiatives Archive News Interviews Editorials Magazines Swiss Venture Capital Report Top 100 Startup Magazine Gründen Swiss Startup Radar Calendar Events Trainings Most viewed Interactive Login Register Twitter … inings Most viewed Interactive Login Register Twitter Get your personal archive Submit an event Submit special offer Contact us About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern
Harvard spin-off CELLVIE raises $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality - MedTech Innovator Open Menu Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager MedTech Innovator Fellows Program Join the Ecosystem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Hea … 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Company Videos Portfolio Companies MEMBER News Press Releases Cohort & Partner News Ecosystem Job Opportunities Log in Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager MedTech Innovato … tem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Heart & Brain Health Accelerator Track MedTech Innovator Plastic Surgery Accelerator Track Webinars 2026 Cohort Companies Company Videos Alumni Portfolio Asia Pacific APAC Accelerator US Market Access Webinars 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Comp … e improving human health Donate Applications for the 2026 Accelerator are Open! Deadline: December 1, 2025 APPLY NOW ×
BioCentury - cellvie: Reviving cell metabolism via mitochondrial transplant This Edition ARTICLE | Emerging Company Profile cellvie: Reviving cell metabolism via mitochondrial transplant Harvard spinout using mitochondrial transfer to treat ischemia-reperfusion injury after kidney transplant By Danielle Golovin, Staff Writer September 25, 2021 2:28 AM UTC Harvard spinout cellvie is pioneering therapeutic mitochondria transplantation as a way to rescue cell energy metabolism and save cells that would otherwise die. James McCully, a cellvie Inc. co-founder, developed the approach at Harvard Medi
Harvard spin-off Cellvie Inc closes $5M seed round - Longevity.Technology Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeutics d … by Kizoo Technology Capital to advance its product pipeline, including a first application in rejuvenation. Longevity.Technology: Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. As powerhouses of the cell, they generate most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to myriad diseases, including neurodegenerative ailments such as … The investment will enable us to pursue the platform broadly, including a first application in aging, where the need for mitochondria-recovery is particularly dear.” “We believe it is time to approach the problem from a different angle … we are hopeful to make a difference in this field.” To date, Cellvie has focused primarily on ischemia-reperfusion injury (IRI), which manifests itself whenever the blood flow to a part of the body is interrupted and subse … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elevian, Oisin Biotechnologies, LIfT BioSiences, MAIA Biotechnology, FoxBio and Turn.bio. “We were immediately attracted to the potential of Cellvie’s approach to emerge as a novel category of medicines,” said Frank Schueler, Managing Director at Kizoo Technology Capital. “With mitochondria dysfunction a common denominator … e the next big category in rejuvenation? R42 Group’s new AI and Longevity Fund participated in a $250,000 pre-seed round for Mitrix Bio ‘s whole-body mitochondrial transfusion research – also joined by the Longevity Tech Fund . Read our exclusive interview with Mitrix’s CEO Tom Benson here. Image courtesy of Cellvie LTUI:
Careers - Regulatory Director (m/f/d) Home Science About us Careers News Contact We are looking for a Regulatory Director (m/f/d) Time commitment : min. 60% – Location : Zürich, Switzerland – Start: as soon as possible At cellvie , we are leveraging the therapeutic potential of mitochondria, which will likely be regulated as a biologic. Based on augmentation and replacement, an approach developed at Harvard, we are building a medicinal platform, with first applications in heart attack patients and organ transplant recipients. cellvie is a venture-backed start-up with primary a
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
CELLVIE presents at the Rejuvenation Startup Summit organized by Kizoo in Berlin Home Science About us Careers News Contact News 14.10.2022 CELLVIE presents at the Rejuvenation Startup Summit organized by Kizoo in Berlin CELLVIE presents at the Rejuvenation Startup Summit organized by Kizoo in Berlin The Rejuvenation Startup Summit created by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry. It is the world's largest gathering of Longevity startups in-person. The Summit brings together startups, members o
Alex Schueller presenting at Rejuvenation Startup Summit 2024 | cellvie LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement
CELLVIE presents at the Rejuvenation Startup Summit 2024 in Berlin Home Science About us Careers News Contact News 10.05.2024 CELLVIE presents at the Rejuvenation Startup Summit 2024 in Berlin The Rejuvenation Startup Summit, brought to you by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry. The summit brings together world-leading rejuvenation startups, members of the rejuvenation/longevity venture capital ecosystem, and the wider investment community. It is the world’s largest in-perso
Cellvie, Berlin Heals, EarlySight, Allasso, Food Founders Studio, Recoveris, Centi, Plair, Inkocell Therapeutics raise funding | Venturelab posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Ag … ja Biopharma and Stylus Medicine —two startups backed by the Myeloma Investment Fund (MIF)—made Endpoints News annual list of the 11 most exciting biotech startups of 2025. Both are focused on developing in vivo CAR T-cell therapy, leveraging game-changing technology that would markedly expand access to this transformational treatment. Check out the full story 👉 https://ow.ly/auR750X1rpO 19 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in LifeSci … 1️⃣ A new venture capital firm, T.Rx Capital, has launched with a $77.5 million fund. It is co-founded by Michael Langer, son of Moderna co-founder Robert Langer, who also serves as the firm's executive chair. T.Rx Capital will invest in early-stage biotech and techbio companies, aiming to reshape disease treatment through the convergence of biology and technology. 📰 https://lnkd.in/ei5nAKrS 2️⃣ California-based venture capital firm Aditum Bio has launched a new biotech, Kal
Cellvie Inc. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Accelerate AI in UK DaltonTx Launches Platform and Partners with Sygnature Oli … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
Careers - Senior Scientist (m/f/d) Home Science About us Careers News Contact We are looking for a Senior Scientist (m/f/d) Location: Zürich, Switzerland – Start: as soon as possible At cellvie , we are leveraging the therapeutic potential of mitochondria. Based on augmentation and replacement, an approach developed at Harvard, we are building a medicinal platform, with first applications in ischemia-reperfusion injury and gene therapy delivery. Cellvie is a venture-backed start-up with primary activities in Zurich and Boston. We are looking for a highly motivated, science-driven mi
MedTech Innovator Names X-ZELL as 2020 Asia Pacific Final Competition Winner - MedTech Innovator Open Menu Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager MedTech Innovator Fellows Program Join the Ecosystem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Heart & Brain Health Accelerator Track MedTech Innovator Plastic Surgery Accelerato … 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Company Videos Portfolio Companies MEMBER News Press Releases Cohort & Partner News Ecosystem Job Opportunities Log in Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager MedTech Innovato … tem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Heart & Brain Health Accelerator Track MedTech Innovator Plastic Surgery Accelerator Track Webinars 2026 Cohort Companies Company Videos Alumni Portfolio Asia Pacific APAC Accelerator US Market Access Webinars 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Comp … e Nov 18 2020 / Categories Company Announcements Startup Receives US$150K Grand Prize for development of an accurate, affordable, and globally scalable early cancer detection from small, 10mL blood samples. LOS ANGELES and SINGAPORE – November 18, 2020 – MedTech Innovator , the largest accelerator of medical devices in the world, in partnership with Asia Pacific Medical Technology Association (APACMed), the first and only regional association to provide a unified voice for th … CEO of X-ZELL. “We feel honored to be recognized as the 2020 Asia Pacific Grand Prize winner. The funding will help us tremendously in bringing our first liquid biopsy to market in Singapore by June next year – the first step in making accurate, affordable cancer screening available to everyone, anywhere in the world.” Selected from a pool of nea
Careers - cellvie Inc. Home Science About us Careers News Contact Careers Together we may succeed To realize the therapeutic potential of mitochondria, to bring about a new treatment modality, it takes a team with wit, dedication and grid. We are looking for entrepreneurial team players who are passionate about making a difference and ready to take on the challenges such an undertaking comes with. We currently have no open roles but are always looking for talented members of the team, please get in touch via [email protected] Current Openings What's new? Explore Copyright © 2026 cellvie In
%PDF-1.7 %���� 820 0 obj > endobj 843 0 obj >/Filter/FlateDecode/ID[ ]/Index[820 39]/Info 819 0 R/Length 115/Prev 4254280/Root 821 0 R/Size 859/Type/XRef/W[1 3 1]>>stream h�bbd```b``M� E ��0X$ D2y�H�F�9 L�� ���%��6��&�A$['� � "�"A�-, ɨ? l��{$2EH�;������ � ��j���W>i�] endstream endobj startxref 0 %%EOF 858 0 obj >stream h�b```�Zv�� " ����������������!�p��KC��Ծ� j�,´O_`�*7���@������K7��g��A�&� �i�[v,~ �OW j� � ���}���̑���A�/��*�c{������n��"֭�We�-=~o��k,:�37G-M�`:Y6;q�= ۄ��� @:��0N�1@4P �QR����n� P&3D)H�XB�T���2�BU����K@̲�𘡢�P��!4X;T� �����Pi� … tream H�\��j�@��}��L.�Q� Bk�?���;�B]e5�}7s�����̙9�_V�J������ִ����� >stream application/postscript ELRIG_UK_logo_2019 Rhona McDonald-Bennett 2020-02-04T10:25:57Z 2020-02-04T10:25:57Z 2020-02-04T10:25:57Z Adobe Illustrator 24.0 (Macintosh) xmp.iid:96ece2de-f6f9-495e-92aa-3e046bfafa79 xmp.did:96ece2de-f6f9-495e-92aa-3e046bfafa79 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:490e0b20-e634-5247-a76e-129338b4144b xmp.did:508e2a3b-7334-4a49-b6db-c9d484faf671 uuid:5D20892 … 00 0.003100 0.003100 Adobe PDF library 15.00 endstream endobj 841 0 obj >stream application/postscript Elrig Drug Discovery Branding Concepts AP (Stacey Peaurt) 2023-10-16T10:12:55+01:00 2023-10-16T10:12:55+01:00 2023-10-16T10:12:55+01:00 Adobe Illustrator 27.0 (Macintosh) xmp.iid:ceaace69-a54c-4822-bbac-2d9c89b02f95 xmp.did:ceaace69-a54c-4822-bbac-2d9c89b02f95 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:cdefe532-89ec-4f35-b963-1eb2acbc3fa6 xmp.did:cdefe532-89ec-4 … 8 2023-04-24T14:41:52+01:00 Adobe Illustrator 27.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:cdefe532-89ec-4f35-b963-1eb2acbc3fa6 2023-09-06T17:00:47+01:00 Adobe Illustrator 27.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:ceaace69-a54c-4822-bbac-2d9c89b02f95 2023-10-16T10:12:55+01:00 Adobe Illustrator 27.0 (Macintosh) / Print AIRobin False False 1 297.00002 … ��\T7ċ���#- �ť����e�������.�8��e��,���ǧ0��^��ۇ���_����X���'#�� >stream application/postscript Print Rhona McDonald-Bennett 2020-02-18T09:57:13Z 2020-02-18T09:57:13Z 2020-02-18T09:57:12Z Adobe Illustrator 24.0 (Macintosh) xmp.iid:8920f39a-d0f8-4675-9730-651800f7ee43 xmp.did:8920f39a-d0f8-4675-9730-651800f7ee43 uuid:5D20892493BFDB11914A859
Biotech startup cellvie gets USD 5.5 million to develop treatments for mitochondria dysfunction About Venture Leaders Programs & Destinations 20 Years Success Stories News --> About Venture Leaders Programs & Destinations 20 Years Success Stories News Upcoming A spin-off of Harvard Medical School that recently moved to a new HQ at the Technopark Zurich, cellvie was built on pioneering research on the potential of therapeutic mitochondria transplantation (TMT). The recently secured funding will be used to accelerate and expand the scientific development of the startup's mitochon … ion potential and fostered the exchange between Swiss and Chinese startups. The application phase for Venture Leaders Biotech 2023 opened today. --> Biotech startup cellvie gets USD 5.5 million to develop treatments for mitochondria dysfunction 06.02.2023 16:45 Morgane Ghilardi The Harvard spin-off, which is a leader in therapeutic mitochondria transplantation (TMT), acquired USD 5.5 million in funding, allowing the startup to be Series A-ready by the end of 2023. … ion potential and fostered the exchange between Swiss and Chinese startups. The application phase for Venture Leaders Biotech 2023 opened today. Related stories cellvie secures USD 5 Million to advance mitochondria-based therapeutics Harvard spin-off cellvie, a biotech company developing mitochondria-based therapeutics, has raised USD 5 million to advance its work in cell therapy. Read more The Venture Leaders Biotech dive into the Boston ecosystem The Venture Lea
CELLVIE CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Award Home Science About us Careers News Contact News 17.06.2021 CELLVIE CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Award cellvie AG is proud to announce that CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Entrepreneurship Award. The W.A. de Vigier Foundation promotes and supports innovative entrepreneurial spirit in Switzerland. Since 1987, the goal of the foundation has been to invigorate emerging companies, providing support to young entrepreneurs, who stand out in the country … out in the country's innovation-rich startup environment. Today, the De Vigier Award is one of the most respected prizes for young entrepreneurs in Switzerland, being awarded for especially high degrees of innovation, value creation for society as a whole, and the technical and financial viability of the founders' company. Every year, entrepreneurs can submit an application for the chance to pitch their idea, project, or company to a jury, in the hopes of reaching the final … f winning CHF 100,000. Due to Covid-19 regulations, this year's first De Vigier Award selection round was held digitally. Out of >200 applications 60 entrepreneurs were selected to present to the De Vigier Foundation jury. Only 17 advanced to the final round, of which 12 were chosen as finalists. cellvie is proud to announce that Alex Schueller, the company's CEO and co-founder, was not only one of these 12 bright minds, invited to showcase their innovations in person, but … amid fierce competition. He was selected as one of six to receive the De Vigier Award's grand prize. The CHF 100,000 contribution will be used to further cellvie's work in Therapeutc Mitochondria Transplantation. Alex founded cellvie together with Drs. James McCully, Pedro del Nido and Sitaram Emani. Born in Germany, he studied business at the Maastricht University in The Netherlands, before joining The Boston Consulting Group. In the subsequent pursuit of his PhD, he came ac … tment modality: the therapeutic use of mitochondria. Alex's presentation at the award ceremony can be watched here: About cellvie AG Started in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. Schueller, Mc
venturelab - Harvard University spin-off and former... Facebook Log In venturelab's Post venturelab September 11, 2025 · Shared with Public Harvard University spin-off and former Venture Leaders Biotech cellvie has just secured USD 5 million to accelerate the development of its mitochondria-based therapeutics. https://www.venturelab.swiss/cellvie-secures-USD-5... cellvie’s kidney transplantation program targets ischemia-reperfusion injury, a major complication when blood returns to restricted tissue, with applications in heart attacks, stroke, and complex surgeries. In addition, a CHF 1.5 … tacks, stroke, and complex surgeries. In addition, a CHF 1.5 million Innosuisse grant is fueling their pioneering mitochondria-enabled gene delivery platform, further expanding therapeutic possibilities. Congratulations to the team for this impressive milestone! #SwissStartups #VLeadersBiotech #Biotech #Innovation #Entrepreneurship All reactions: 3 Like Comment
%PDF-1.6 %���� 6820 0 obj >stream hެY�r�6��� ��Ką3��H�不k7vڴI h ���V�N�~}w]h �E��!��p�.|@knK��V�T�3e25d(�J_�Y&�q�3�,�)��2�uBV�0n��8�6�d &���e� ���2!K�bBf��fB)o�2��2a��2&�-�N-�$7�LJ�-ɤ5Y)�]z Wa��4SB{�0%i�4 �[S�f/��24{�9SqA �'��� Fh�Mk��Tx o)�Rp��F�T�x o�V��g&I�ř~B��W)$3���Dʌ�3�-hH �F�� g��p�ʪd*K����k7�Ѡ��D ���lyY�eQ~�k�^��Ϯ��q���4 a8��gx�Ns�h>��Kp��n:��[ø���n�����͠���3L` 3�3s��}�|�f~ o�QpF�Pz�,&w%� ��+7�����B��K���+*,���M�0��}��� ͫ��v� T�����?p_�_��K���=���$�)qG������? %� �O�Ŭҟ�K��b��O��%�:xsz~��3�rUL]yT�i�O�agv3q,���Mç�z���bQ͗�~�l�t���t�$�?�G … 2��i����z(K!��p� ����)�|� !�;��K��+��`�Chi endstream endobj 24 0 obj >stream application/postscript Print 2025-12-31T22:38:59+08:00 2025-12-31T22:38:59+08:00 2025-12-31T22:38:59+08:00 Adobe Illustrator 29.5 (Windows) 256 168 JPEG /9j/4AAQSkZJRgABAgEAAAAAAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAAAAAAAAEA
AQAAAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8f … 000 0.003100 0.003100 Adobe PDF library 15.00 endstream endobj 25 0 obj >stream application/postscript 218国证国际 (short) 2025-06-16T12:19:00+08:00 2025-06-16T12:19:00+08:00 2025-06-16T12:18:59+08:00 Adobe Illustrator 28.7 (Windows) 256 196 JPEG /9j/4AAQSkZJRgABAgEAAAAAAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAAAAAAAAEA
AQAAAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8 … de8 2025-06-16T12:19:00+08:00 Adobe Illustrator 28.7 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator Print AIRobin False False 1 705.555556 132.291667 Millimeters Cyan Magenta Yellow Black 預設色票群組 0 白色 CMYK PROCESS 0. … 000 0.003100 0.003100 Adobe PDF library 17.00 endstream endobj 26 0 obj >stream application/postscript 218国证国际 (short) 2025-06-16T12:19:00+08:00 2025-06-16T12:19:00+08:00 2025-06-16T12:18:59+08:00 Adobe Illustrator 28.7 (Windows) 256 196 JPEG /9j/4AAQSkZJRgABAgEAAAAAAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAAAAAAAAEA
AQAAAAAAAQAB/+4ADkFkb2Jl
cellvie Presents at CEOT 2026 Home Science About us Careers News Contact News 26.02.2026 cellvie Presents at CEOT 2026 Scottsdale, Arizona – February 26, 2026 – Cellvie was invited to present at the AST Cutting Edge of Transplantation (CEOT) meeting, where the company showcased its novel approach of mitochondria transplantation for the treatment of ischemia-reperfusion injury. CEOT is organized by the American Society of Transplantation , one of the leading professional organizations in the field of organ transplantation. The meeting brings together top clinicians, researchers, and … team is focusing on ischemia-reperfusion injury as the technology’s first application - a thus far intractable disease pathology and leading cause of death arising in heart attacks, stroke, or organ transplantation. cellvie believes in the platform potential of mitochondria honing a pipeline of applications in the fields of cell and gene therapy and longevity. Back to news Copyright © 2026 cellvie Inc. - All Rights Reserved. Home Science About us Careers News Conta
%PDF-1.7 %���� 2734 0 obj > endobj 2757 0 obj >/Filter/FlateDecode/ID[ ]/Index[2734 41]/Info 2733 0 R/Length 106/Prev 7275762/Root 2735 0 R/Size 2775/Type/XRef/W[1 2 1]>>stream h�bbd``b�� �@�i�`K��A�������f�X�A�o �8��cn@�+H�Mꛀ����Y��$ u��lAV20R���#�#@�`` endstream endobj startxref 0 %%EOF 2774 0 obj >stream h��V�s� �>�{�r9�v/������].ɑ�9L� � !F�%�I��(A��q�±P�"�_�V��3N@�ut�W��v�A�R~�0�i���j ;�3m��ٽ�d�_���� 2�|%�B���9~��\�����ϩPDA��+g#r �U��G*C"�9#��X�1\m W�����Z]���o���y�����F0�˜�>��ؼ��Gj�*bH�#���� M� Z�X��D CM�W �b��S`��r.ūJ$�!Kꝋ�(�9����LJ*2��.]v … :9f27a4e5-4168-4783-9041-ef38c4d07467 uuid:26724c3d-3e3f-42db-baac-38395267c6c8 application/pdf endstream endobj 1245 0 obj >stream hޜ�1O1 ��J��%��8RՅ����C%N����]� kU��9>��=�N����t��mű���WsR�5(����$ �v������+�O�����KsN��`�&([ k�4=�|����2���?*�Um���"֠�qbX� �z�Y`#��Df�eh3� J�q��#� N��*56v�bD`ض��O*j4�*ӫl�`����E_m�@�ރ������� �Z*��$ �Z����nT9 >stream h�2276V0P���w.JM,���sI,I�p�22023�&��F�������)� ,��� ��SJ�S�4R�J��s��]�5�� �$� endstream endobj 1247 0 obj
Taiwan - Biotech Companies - Careers Page About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact Taiwan - Biotech Companies - Career Pages , Stopped work Aug 2025, IP company Ossis , 3D-printed orthopedic implants mAbRx , Gone Bostal Pharma Edison, NJ Drug delivery technologies, Generics Sentrimed Mullica Hill, NJ Oral Therapies Targeting Podoplanin ATXA Therapeutics Dublin, Ireland Cardiopulmonary Treatments PEAR Therapeutics , Chapter 11 Bankruptcy, Apr 2023 Pfizer Lake Forest, IL Sterile … ased expandable cage technology Biopraxis , No website no info. 1996 SBIR grant. Seems to be an umbrella group NeoPharm , Merged with Insys Therapeutics CG Pharmaceuticals , Website down Apr 2025 - Sep 2025 Hygia Health Services , Acquired by Stryker, May 2018 Candel Therapeutics Needham, MA Oncolytic Viral Immunotherapies for Cancer Pronova BioPharma , Acquired by BASF, Jan 2013 Peptilogics Pittsburgh, PA Peptide Therapeutics A … 010, $800M , No news 2017 - Apr 2026 Carigent Therapeutics , Had a grant in 2008. No info for a long time Rhaeos Evanston, IL Shunt Monitor TopoGEN Buena Vista, CO Assays, Antibodies, Cell Repair, Services , Acquired by Sebia, Sep 2024 , Winding down Jan 2026 Riverside Clinical Research , Renamed Velocity Clinical Research RGenix , Renamed Inspirna, Sep 2021 Ablitech , Website Gone 12-10-13, No longer a tenant at last k … annabinoid Database CERAMIDE THERAPEUTICS , No info. Jun 2015. $1.5M SBIR grant 2011 Corus Pharma , Bought by Gilead, Aug 2006 Swedish Orphan Biovitrum Waltham, MA Biologics Vedere Bio , Renamed Vedere Bio II ayfter most assets acquired by Novartis, Oct 2020, $150M + $130M Milestones GBI Biomanufacturing Plantation, FL Contract Biologics Manufacturing and Development , Website down May 2025 - Dec 2025 Cytex Therapeutics , Renamed Cyt … on Channel Innovations , Primitive website, no apparent employees. Got $1M SBIR grant in 2013 Crown Bioscience Beijing, China Drug Development , Selling pipeline, winding down Jul 2025 , Renamed Genetix Biotherapeutics, Sep 2025 , Filings late Mar 2025 - Feb 2026 Regulus Pharmaceutical Consulting , Acquired by Cli
%PDF-1.6 %���� 2252 0 obj >stream h��m��F�������Ÿ/�2�ۆ��mc��,V%�ԭEKeHj���w��H�0�*�%U)9%� I�$ '�2"-�E^�Tm!�B����B��E� ���Y�-R��TuQ�i���&--$E%C��%�L�yl�8EZ� ��HZ�8��ͪŖ�"y�BmX�"%~�Z�q�q���a��|��uB��ؒ\�¢$�kZ��-�.,j/�Yl�����S���qnmq����m%����q M�dḶ�bˠ1Ǔ���K9�А��c� �>�=kM�-kh Z^����!ר=�x`]w���Z �5� P+x���\rZ�V�6j�7d���N���� Y��I=�i������x�k��c�Bp �t����7�����At���-����ӟ�_�9���������O5�������w�/�^ ����Û�����/^��m ��������ד�'���N^���?�z�⤝���>���d�/O�I�-�m��2���?��%�}����I�=9���|?q��r�"Q5��88�,N�����?߾8��糿�X�ӿ��7���q��?�� ����Q����Q�P�H�7.��� �p����~����� … 9\�m�I�a�d3�fP�t���^fŗU(W�f�� U��}9��Q��i�?�e��0ѫ�S���]������� >stream application/pdf YRWY704_MM_InsideFrontCover_0223._Fai 2023-02-24T14:02:24-05:00 2023-02-24T14:02:24-05:00 2023-02-24T14:02:24-05:00 Adobe Illustrator 27.2 (Macintosh) uuid:31aa04e6-895b-6b46-9b29-52640a9f8c71 xmp.did:f2215791-cae5-47b8-a723-1e598da7b2f5 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:89752d56-4d50-0f47-b8fc-f06dd7ca9512 xmp.did:687ac151-97dc-4e3d-97dc-fbfb378d7964 uuid:5D2089 … X�pl%3,�Q�C�~�[:����'~I���>� � 0��#\�Fa��Ѵ�����v1IH��}�a�Bk� ,��v8 >stream application/pdf YRWY704_MM_InsideFrontCover_0223._Fai 2023-02-24T14:02:24-05:00 2023-02-24T14:02:24-05:00 2023-02-24T14:02:24-05:00 Adobe Illustrator 27.2 (Macintosh) uuid:31aa04e6-895b-6b46-9b29-52640a9f8c71 xmp.did:f2215791-cae5-47b8-a723-1e598da7b2f5 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:89752d56-4d50-0f47-b8fc-f06dd7ca9512 xmp.did:687ac151-97dc-4e3d-97dc-fbfb378d7964 uuid:5D2089 … 100 Adobe PDF library 17.00 endstream endobj 12 0 obj > endobj 13 0 obj >stream application/postscript TMM logo_Orange (Marc Bird) Adobe Illustrator 24.0 (Macintosh) 2020-08-10T10:22:09+01:00 2020-08-10T10:22:09+01:00 2020-08-10T10:22:09+01:00 xmp.did:3a186939-e486-48c7-b6c7-75ecccd12dd9 xmp.iid:d583b707-244e-4a71-9a41-bebe3dde220e uuid:893EF87D4EB7E311A3F4A0BF1A31319E proof:pdf xmp.iid:1b62eb91-ba4a-4770-9b6a-86eb9868ae57 xmp.did:1b62eb91-ba4a-4770-9b6a-86eb9868ae57 uuid:893 … 017-08-30T16:25:37+01:00 Adobe Illustrator CC 2017 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3a186939-e486-48c7-b6c7-75ecccd12dd9 2020-08-10T10:22:09+01:00 Adobe Illustrator 24.0 (Macintosh) / converted from appl
BioAlps News - BioAlps Skip to content Bio Alps FIND A HEALTH VALLEY ACTOR Menu Search News BioAlps news BioAlps 20 years Events About Mission Organization Members and Strategic Partners BioAlps Awards Media Center News Events BioAlps events Life science events About Mission Organisation Executive Committee BioAlps Team -- Members and Strategic Partners BioAlps Awards Media Centre Publication -- --> BioAlps Event Formats Business Opportunities Community Membership Registration The BioAlps Community Business opportunities Community Membership Registration The BioAlps Community Job Opportunities … velop a new treatment… News 16.06.2026 Actival Shines at >>venture>> 2026 Award Ceremony The annual >>venture>> Awards, held at the Swiss Tech Convention Centre at EPFL in Lausanne in front of around 300… News 16.06.2026 NIRLAB Acquired by 908 Devices NIRLAB, the Swiss startup behind a handheld near-infrared (NIR) spectroscopy platform, has been acquired by 908 Devices. The ＄23 Million… News 15.06.2026 AC Immune Receives $4 million from The Vijay and Marie G … earch… News 15.06.2026 Precise Health Gets a CHF 900’000 Innosuisse Grant The Valais-based startup and EPFL spin out will use the funds to develop PhageMatch™, an AI powered platform that helps… News 12.06.2026 Tracy Laabs Appointed Director of the Wyss Center for Bio and Neuroengineering The Wyss Center for Bio and Neuroengineering, one of the 17 academic institution partners of BioAlps since 2024, has announced… News 12.06.2026 Eight Projects Selecte … France and even Lebanon. The goals of… News 12.06.2026 Bioscibex Wins BCV Prize and Ships its First Devices Bioscibex, the Valais biotool startup born out of EPFL and based at the BioArk in Monthey, is having a banner… News 11.06.2026 CSEM and the EPFL spin-off ORYL Photonics win first prize at the 2026 EARTO Innovation Awards On 10 June 2026, CSEM received the EARTO Innovation Award in the “Impact Expected” category for the development of a… News 11.06.2026 … of a… News 11.06.2026 Crìa Technologies Winners of a 2026 W.A. de Vigier Award A Geneva-area startup has earned a place among Switzerland’s most prestigious recognitions for young entrepreneurs. Crìa Technologies SA, based in… News 11.06.2026 Atinary Selected as a 2026 Technology Pioneer by the World Economic Forum Atinary, a p
Galvanize Therapeutics raises $100M in Series C, led by Sofinnova Partners | Jesse Landry posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … edical Technologies , Ally Bridge Group , Perceptive Advisors Xontogeny Venture Fund, Janus Henderson Investors , and Longaeva Partners LP . Returning believers include Fidelity Management And Research Company , T. Rowe Price , Gilmartin Capital LLC , Intuitive , and founding investor ATP (Apple Tree Partners) . When capital stacks this deep, it’s not curiosity, it’s conviction. Galvanize didn't stumble into this. Apple Tree Partners engineered the merger of Gala Therapeutics … ience. ⏳ Backstory: NRG was founded in 2018 by Neil Miller, Richard Rutter, and Grant Hawthorne. Despite the initial struggle to attract investors, the firm survived on grants from groups like Parkinson’s UK and the Michael J. Fox Foundation until it raised £16M in Series A in 2022. This £50M Series B was led by SV Health’s Dementia Discovery Fund, with backing from Merck KGaA and Novartis' venture arms. 🔎 Zoom in: NRG-5051 has a mechanism that blocks mPTP, a mitochondrial p … by neurodegenerative disorders.” Led by SV Health Investors’ Dementia Discovery Fund and joined by British Business Bank, M Ventures, Novartis Venture Fund, and others, the funding will propel NRG’s lead candidate NRG5051 into clinical trials for ALS/MND and Parkinson’s disease starting in early 2026. Read more https://lnkd.in/eaGpkKaM #therapeutics 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 16,157 followers 3000+ Posts 406 Articles View P
BioSpace - With $52 million series A, Appia Bio... Facebook Log In BioSpace's Post BioSpace May 11, 2021 · Shared with Public With $52 million series A, Appia Bio anticipates a bright future in cell therapy biospace.com With $52 Million Series A, Appia Bio Anticipates a Bright Future in Cell Therapy | BioSpace All reactions: 15 1 share Like Comment
Annual Review of CSEM's Tools for Life Sciences Innovations English Français Deutsch Digital Journey 2026 Our expertise Technical focus Industrial focus Tailored services How to collaborate with us IP policy and confidentiality European projects News & more News Events Blog About us Awards and Certifications History and Start-ups Governance Annual Reports Working at CSEM Jobs Back2Business program ACCELERATE start-up program Press and Publications Press room Downloads YODA Open access platform Contact Digital Journey 2026 Our expertise Technical focus Additive manufacturing ASICs for
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Alexander Rabchevsky - University of Kentucky Skip to main navigation Skip to search Skip to main content University of Kentucky Home LOGIN & Help Link opens in a new tab English Español Search content at University of Kentucky Home Research units Researchers Projects & Grants Research Output Facilities & Equipment Honors & Awards Activities View Scopus Profile Alexander Rabchevsky, Ph.D. Professor, SCoBIRC Endowed Chair #1 Professor , Physiology Neuroscience Research Priority Area Spinal Cord and Brain Injury Research Center https://orcid.org/0000-0002-1991-0915 h-index … Bethesda, MD AWARDS aND HONORS 2020 Albert Nelson Marquis Lifetime Achievement Award, Marquis Who’s Who 2019 Tom Gravitt Advocacy Award, Kentucky Congress on Spinal Cord Injury, KY 2019 Friend of Year Award, Friends for Michael, Inc. Spinal cord injury organization, KY 2018 - present Unite 2 Fight Paralysis, Board of Directors, Minneapolis, MN 2018 - present NextStep Raleigh, Board of Directors, Raleigh, NC 2018 - 2020 North American Spinal Cord Injury Consortium (NASCIC), E … 016 - 2019 National Neurotrauma Society, Council Member 2013 James W. Holsinger Award for Excellence in Teaching, Department of Physiology and the College of Medicine, University of Kentucky 2010 - 2018 No Barriers USA, Board of Directors member, Fort Collins, CO 2008 James W. Holsinger Award for Excellence in Teaching, Department of Physiology and the College of Medicine, University of Kentucky 2006 Abraham Flexner Master Educator Award for Outstanding Teaching Contribution, … in Medical Education, University of Kentucky 2004 - 2021 Charles T. Wethington Award, Excellence in Research, University of Kentucky 2004 Appointment to SCoBIRC Endowed Chair #1, University of Kentucky 2004 Provost Retention Award, College of Medicine, University of Kentucky 1999 National Research Service Award, Postdoctoral Fellowship, NIH/NINDS (University of Kentucky), Mechanisms of bFGF effects after spinal cord injury. Declined 1994 Poster Excellence Award, 12 th Nation … ional Neurotrauma Society Symposium, Miami, FL 1994 Graduate Assistant Teaching Award, Medical Neuroscience, COM, University of Florida, Gainesville, FL 1991 - 1993 Pre-Doctoral Studentship Award, Rick Hansen Man in Motion Legacy Fund, Canada, Dept of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 1988 Graduated one sem
CELLVIE: Reviving cell metabolism via mitochondrial transplant Home Science About us Careers News Contact News 27.09.2021 CELLVIE featured in Biocentury's Emerging Company Profile Harvard spinout cellvie is pioneering therapeutic mitochondria transplantation as a way to rescue cell energy metabolism and save cells that would otherwise die. James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when the blood supply returns after a period of ischemia. "What Jim observed in conditions o
Beiersdorf CVC made a new investment in Life Sciences! We’re thrilled to announce, that our team at Beiersdorf Corporate Venture Capital has made a new investment in cellvie, a pre-clinical-stage… | Chunchun Yao LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any … Series B to Advance Programmable mRNA Therapies. 🔬 Shattuck Labs secured $103M fund to support Phase 1 and multiple Phase 2 trials of SL-325. 🌱 Fermelanta, Inc. Raises $13.8M Series A to Scale Microbial Production of Plant Metabolites 🎯 Also in the spotlight: Geltor , iSelect Fund , Washington University in St. Louis , Colorcon Ventures , Phytolon , SNIPR Biome - A CRISPR Company , Cystic Fibrosis Foundation , Lundbeckfonden BioCapital, UC Santa Barbara , National Science … es. 🏆 Perfusion Medical Wins Crab Trap: Reston-based startup took home the top prize with therapy PM-208, while Chariot Biosciences earned $10K in CRO services. ⚗️ Advanced Research Projects Agency for Health (ARPA-H) GIVE Program: New initiative launched to revolutionize biomanufacturing for cell and gene therapies, addressing cost and complexity in production. 🏭 GSK Expands Rockville Manufacturing: Despite exiting its vaccines R&D hub, the pharma giant will invest par … ulator R-2487 into clinical testing for Sjögren’s disease. 🌟 PQE Group US Wins Award: Named “Best Life Sciences Company in Maryland” by the Stellar Business Awards for innovation, leadership, and industry impact. https://lnkd.in/gs4yMdmN 25 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Vincent Zucconi 8mo Report this post 🚀💥🌟🎉 Biotech bonanza alert—therapeutic innovations are electrifying the industry! 🧬🔬✨🌈 The global biotechnology mark
cellvie secures $5 million to accelerate clinical translation News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Capital Re … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout cellvie secures $5 million to accelerate clinical translation Financing Please login or register 09.09.2025 cellvie, a pioneer in mitochondrial-based therapeutics, has secured fresh funding from both existing and new investors. The round was led by Taiho Ventures, with major contributions also coming from another existing investor, Kizoo Technology Capital, and Beiersdo … rom the therapy. In a second program, supported by a CHF 1.5 million Innosuisse grant, cellvie is developing a mitochondria-enabled gene delivery platform that leverages the organelle’s unique biodistribution and efficient cellular uptake. The biotech company, established in 2018, has now received $5 million of fresh capital to accelerate the development of its lead asset towards clinical translation and to further hone its pipeline. The funding round was led by the existing … Register for more services Create your personal archive Get the Newsletter Set award alarms Partners Contributors Supporters Supporters News Startup Media House Pinboard News archive Newsletter archive Editorials Directories Awards Grants & Loans Jobs Investors Facts Initiatives Archive News Interviews Editorials Magazines Swiss Venture Capital
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
%PDF-1.4 %���� 1 0 obj > /StructTreeRoot 3 0 R /ViewerPreferences 4 0 R /Lang (en) >> endobj 5 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > /XObject > >> /MediaBox [0.0 7.9200063 612.0 799.92] /Contents 643 0 R /StructParents 0 /Parent 6 0 R /Tabs /S /BleedBox [0.0 7.9200063 612.0 799.92] /TrimBox [0.0 7.9200063 612.0 799.92] >> endobj 12 0 obj > /XObject > /Font > >> /MediaBox [0.0 7.9200063 612.0 799.92] /Contents 649 0 R /StructParents 1 /Parent 6 0 R /Tabs /S /BleedBox [0.0
CSEM and cellvie automate mitochondria isolation for clinical use Skip to content Services Key industries Why Switzerland News Contact us Services Key industries Why Switzerland News Contact us Data protection Impressum English Français ( French ) Vous êtes ici: Home Life sciences CSEM and cellvie automate mitochondria isolation for clinical use CSEM and cellvie automate mitochondria isolation for clinical use Life sciences 9 September 2025 (Left to Right) Alexander Schueller, Founder and CEO; This Egloff, Scientist (cellvie); Charlotte Fonta, Senior R&D Engineer; and Gilles Weder, Head R … manipulation, limiting scalability and consistency. Supported by an Innosuisse grant of over CHF 700,000, CSEM and cellvie have re-engineered the process into a single automated workflow, ensuring compliance with Good Manufacturing Practice (GMP). “Establishing a robust and scalable system for mitochondria isolation is essential to ensure bioenergetic functionality and safety, and paves the way to bringing revolutionary mitochondrial therapies one step closer to the clinic,”
Exhibiting Companies ® Digital, November 2–4, 2022 | Virtual, conference, meeting, biotechnology, event, biotech, ebd, pharma, finance, venture, capital, partnering"/> ® Digital Exhibiting Companies"/> --> --> --> Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC Informa PLC About us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Informa 3 days in-person. 3
Kizoo Portfolio Company Underdog Closes $10M Financing Round - Cyclarity Therapeutics Skip to content Home Our Science Team News & Publications Supplementary Material Investors Contact Us Career Opportunities Home Our Science Team News & Publications Supplementary Material Investors Contact Us Career Opportunities Kizoo Portfolio Company Underdog Closes $10M Financing Round By Cyclarity Therapeutics September 23, 2021 Press Release Mountain View, CA, U.S., September 23, 2021 – Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has close … egin clinical trials in 2023. Mike Kope, Underdog Co-CEO, said: “The ILAP award together with the new funds will enable us to further advance to deliver a simple and affordable preventive therapy for the world”. “We are really into this. This is the first deployment from our $360M commitment to fund the most promising rejuvenation startups through follow-up rounds to advance the therapies from clinical development to public availability”, said Frank Sc … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others. Forever Healthy’s other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference. Further infor
Harvard spin-off CELLVIE raises $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-onl … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Cellvie: Funding, Team & Investors | Startup Intros Home / Organizations / Cellvie § Private … heart attacks, strokes, organ transplantation, and long surgeries—with its lead application in kidney transplants to reduce delayed graft function affecting up to 50% of recipients.[1][2][5][7] The company serves patients in critical care and transplant settings, addressing root causes of cellular failure where current treatments fall short, while exploring broader uses in aging-related degeneration.[1][2][7] Founded in 2018 in Zurich, Switzerland, Cellvie has raised over $10
Falling Walls - 🧬 The next breakthrough therapy could come... Facebook Log In Falling Walls's Post Falling Walls March 5 · Shared with Public The next breakthrough therapy could come from your lab As part of the Falling Walls Global Call 2026, Falling Walls Venture, in partnership with Boehringer Ingelheim , is looking for biotech start-ups turning scientific discoveries into therapies and platform technologies with real clinical impact. If you know a biotech start-up that interested in pitching to our international audience of investors and industry leaders, nominate them here: https:/
Beiersdorf CVC invests in cellvie, a biotech company focused on mitochondria transplantation. | Gunes Bozkurt, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl … Series B to Advance Programmable mRNA Therapies. 🔬 Shattuck Labs secured $103M fund to support Phase 1 and multiple Phase 2 trials of SL-325. 🌱 Fermelanta, Inc. Raises $13.8M Series A to Scale Microbial Production of Plant Metabolites 🎯 Also in the spotlight: Geltor , iSelect Fund , Washington University in St. Louis , Colorcon Ventures , Phytolon , SNIPR Biome - A CRISPR Company , Cystic Fibrosis Foundation , Lundbeckfonden BioCapital, UC Santa Barbara , National Science … es. 🏆 Perfusion Medical Wins Crab Trap: Reston-based startup took home the top prize with therapy PM-208, while Chariot Biosciences earned $10K in CRO services. ⚗️ Advanced Research Projects Agency for Health (ARPA-H) GIVE Program: New initiative launched to revolutionize biomanufacturing for cell and gene therapies, addressing cost and complexity in production. 🏭 GSK Expands Rockville Manufacturing: Despite exiting its vaccines R&D hub, the pharma giant will invest par … ulator R-2487 into clinical testing for Sjögren’s disease. 🌟 PQE Group US Wins Award: Named “Best Life Sciences Company in Maryland” by the Stellar Business Awards for innovation, leadership, and industry impact. https://lnkd.in/gs4yMdmN 25 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in WayBio 338 followers 9mo Report this post Proud to introduce WayBio to the Boston biotech community. We’re building a partner-first approach to plasmid DNA desi … investment case. In other words: the cleanest technology is also the easiest to fund. cell_and_gene_position_paper.pdf invivo.partners 15 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in BiopharmIQ by Amp 4,624 followers 9mo Report this post 📊 𝗔𝘂𝗴𝘂𝘀𝘁 𝗕𝗶𝗼/𝗣𝗵𝗮𝗿𝗺𝗮 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝗧𝗿𝗲𝗻𝗱𝘀 powered by Bi
cellvie featured in Gen Suisse: advancing gene therapy through mitochondrial innovation Home Science About us Careers News Contact News 21.04.2026 cellvie featured in Gen Suisse: advancing gene therapy through mitochondrial innovation Zurich, Switzerland - April 21, 2026 - The article, written by Gen Suisse , features cellvie’s work in leveraging mitochondria as gentaxis , enabling new ways to deliver genetic material within the body. This concept has the potential to address key limitations of existing delivery technologies , particularly in terms of delivery payload capacity, in vivo d … that LNPs or viral vectors have so far been unable to deliver into cells. First Application: Treating Epidermolysis Bullosa cellvie plans to bring its gene vector technology into clinical use for the first time in the treatment of epidermolysis bullosa (EB), a rare hereditary disease in which even minor mechanical stress causes severe skin injuries. Affected individuals suffer from chronic wounds, persistent pain, and a significantly elevated risk of infection. The focus is o … t program to advance the development of mitochondrial gene therapy vectors. The grant underscores the importance of such platform technologies for Switzerland as a hub for biotechnology. In Switzerland, mitochondrial therapies would likely be classified as biological medicinal products and fall under the Therapeutic Products Act. The precise regulatory classification remains open, however, as mitochondria used as gene therapy delivery vehicles represent an entirely new produc … hicles represent an entirely new product category. Outlook The path to clinical application is still long. But the potential is enormous: if the mitochondrial approach proves its worth, it could make gene therapies safer, more broadly applicable, and independent of viral systems. For patients with diseases affecting hard-to-reach organs, that would be a breakthrough. And for Switzerland as a research and innovation hub, it would be further proof that the country is not only c … team is focusing on ischemia-reperfusion injury as the technology’s first application - a thus far intractable disease pathology and leading cause of death arising in heart attacks, stroke, or organ transplantation. cellvie believes in the platform potential of mitochondria honing a pipeline of applications in the fields of cell and gene th
%PDF-1.5 %���� 1084 0 obj > endobj 1197 0 obj >/Filter/FlateDecode/ID[ ]/Index[1084 222]/Info 1083 0 R/Length 364/Prev 5438937/Root 1085 0 R/Size 1306/Type/XRef/W[1 3 1]>>stream h����+Dq����\3e�!6 �I�Lٱ �X��$��Ȃ�dC�x�XX�ң�P� �(Y�$;��|��YZX��������sϽֈDĊU�S�+5 S۪mQM��1�3jaZu�Ȕ� ���$�qw�>t��j"�Ff�����2X�H �^�k=M���]5���%�Gev#�7���nc��f�ح��@]f�����yfp��igcמn���)��}�Ub6o7ɤ�.� {�l�wMkֻg2 L�s�����4V���.1:l��L�u� �|h���Ƒ-��S��?!�@7���)�:\ᛯ_�$&5.z�|�k$xɟ#&g���~�O��"��? n�?� endstream endobj startxref 0 %%EOF 1305 0 obj >stream hޤ�_lSU ǿ��v-�Mwo{�� ^Z�0l���D�0'$&t�@ f��E����� �lZ … ⬊YŬ�5�&�3��⊹"fgEΊ�9+vV��G��f M>�}4�h����G���8�!�O��o�|���B�6ƫ�G�� >stream application/postscript 21640 - Mitochondria Targeted Therapeutics logo_NEW Daniel Elliott 2021-10-12T13:56:59+01:00 2021-10-12T13:56:59+01:00 2021-10-12T13:56:59+01:00 Adobe Illustrator 25.2 (Macintosh) xmp.iid:a381136a-f33c-4861-bce5-53a1a70e200f xmp.did:a381136a-f33c-4861-bce5-53a1a70e200f uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9c21ad0e-4af9-4448-b973-8db87d0ef907 xmp.did:9c21ad … 610890 2020-11-26T17:40:54Z Adobe Illustrator 24.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4eed2328-5be5-40b8-b3fa-160472aa31c3 2020-12-14T11:34:53Z Adobe Illustrator 25.0 (Macintosh) / saved xmp.iid:ebf93fd6-38ad-469f-98ed-33d16b216654 2021-10-12T09:20:47+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:9c21ad0e-4af9-4448-b973-8db8 … 7 2021-10-12T13:55:01+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:a381136a-f33c-4861-bce5-53a1a70e200f 2021-10-12T13:56:59+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator Print Adobe Illustrator Adobe PDF library 15.00 1 True False 444.762974 201.626845 Millimeters NexaLight Nexa Light Regular Open Type Version 1.000 Fal … ƽ�;���M���P���+����9ę� T6L�wr,�~ ��f endstream endobj 1147 0 obj >stream application/postscript Print Daniel Elliott 2017-06-21T21:22:05+01:00 2017-06-21T21:22:05+01:00 2017-06-21T21:22:04+01:00 Adobe Illustrator CC 2015 (Macintosh) xmp.iid:6fd5c0ba-886c-4847-a42f-d9f2d2a03e85 xmp.did:6fd5c0ba-886c-4847-a42f-d9f2d2a03e85 uuid:5D20892493BFD
Longevity progress in 2022 - quadraScope Ventures --> --> --> --> --> --> --> --> --> --> --> Skip links Skip to primary navigation Skip to content li > a"}'> Home Science Portfolio Team Videos LOGIN Toggle navigation Home Science Portfolio Team Videos Download PDF Longevity biotech progress in 2022 Despite the economic challenges of 2022, the emerging longevity biotech industry made impressive progress on several fronts, including positive results in clinical trials of senolytics and mitochondrial replacement therapies. Contents Unity succeeds at preventing blindness through senolytic therapy … returns for private investors, leaving it up to the philanthropic community to fund these important projects. Non-profits, including Dr. Aubrey de Grey’s new Longevity Escape Velocity Foundation ( LEVF ) will be undertaking some of this work. On a related topic, the NIH runs the Interventions Testing Program ( ITP ) to identify and validate treatments that extend lifespan and healthspan in mice. Unlike for-profit companies, programs like the ITP are known to be transparent a … is sponsored by the Saudi government. The foundation committed $1B per year to fund longevity research and invest in longevity biotech companies. In 2022, Hevolution awarded $8.5M to fund American Federation for Aging Research New Investigator Awards, $2M to sponsor Longevity Impetus Grants, $2.6M to support geroscience research in Saudi Arabia, and $5M to support grants reviewed by the National Institute on Aging. Publicly announced funding that we can account for amounts t
Cellvie Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech stack Market
%PDF-1.6 %���� 1495 0 obj > endobj 1528 0 obj >/Filter/FlateDecode/ID[ ]/Index[1495 66]/Info 1494 0 R/Length 140/Prev 10853425/Root 1496 0 R/Size 1561/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"�$�I0[ Dr���. �ILf�I �x�-&��I^$0�L���� ��D���H�6)�DjIF�E`���b��s@$�>�� >stream h��}Pwǟ�MBBI���jb%g�R��5�K��vB �Z`���� �Z��`řH}���/h}��� -�)�7�'M v쩵R�+�^�v7�z7ӛ�����$���{���ͳ;� (uC@h!H��Cl*�n��ϧ�$�In�!+B F��U,�(�D�J����z���vS����>�o� �V��TJh���V��)c�I��y��C9�vA���ēx�y��7�ة���?;&; G���J�=i� [��f�|��U��m��xC�z7_��=�u���}���.3��]�=�[Szq����v�c���� [vO�e� … }yn-6���{�wz`����֜a�����7������ '_ pV�� endstream endobj 1523 0 obj >stream application/postscript Greg Nielsen SBT-Logo-TM-4c-pos.eps Adobe Illustrator CS2 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 uuid:24EBF3E16E8511DA9E4086E538E29E18 uuid:24EBF3E26E8511DA9E4086E538E29E18 endstream endobj 1524 0 obj >>>/Subtype/Form/Type/XObject>>stream H�2P��*�2PAC�l.}�`��b.#=Cs#=#s csC= ] ��H�(�+�+� �n� endstream endobj 1525 0 obj >/ProcSe … ����J�`� �L|0�@��#���24��[w���AX������ �u� endstream endobj 3 0 obj >stream application/pdf LONZA_LOGO_MAIN-BLK 2021-01-28T18:30:46Z 2021-01-28T18:30:46Z 2021-01-28T18:30:46+01:00 Adobe Illustrator 25.1 (Windows) uuid:a3de2334-99ae-43ee-9bbd-741f79caa74a xmp.did:4b30f76e-9211-bb47-ab33-a3600ddfe9ba uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9963990e-1bd9-b545-9ca6-06946215f430 xmp.did:9963990e-1bd9-b545-9ca6-06946215f430 uuid:5D20892493BFDB11914A8590D31508C8 … 6215f430 2021-01-28T18:06:09Z Adobe Illustrator 25.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4b30f76e-9211-bb47-ab33-a3600ddfe9ba 2021-01-28T18:13:17Z Adobe Illustrator 25.1 (Windows) / Print AIRobin Document False False 1 134.166337 51.249506 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 29 29 27 CMYK Red RGB PROCESS 227 6 19 CMYK Yellow RGB PROCESS 255 … ) 2024-01-31T09:39:48+01:00 2024-04-10T08:57:56+02:00 2024-04-10T08:57:56+02:00 application/vnd.adobe.photoshop 4 Coated FOGRA39 (ISO 12647-2:2004) xmp.iid:c6d133e2-6c37-4c43-a5c7-2d2003c911c9 adobe:docid:photoshop:cbdeaaad-f9b2-a14f-b3b0-3fa9427c4f33 xmp.did:31c8d117-0238-4925-9f3f-74244c25ee44 created xmp.iid:31c8d117-0238-4925-9f3f-74244c25ee4
%PDF-1.4 %���� 1 0 obj > endobj 4 0 obj > endobj 3 0 obj > endobj 2 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj
Portfolio - Beiersdorf Venture Capital Jump directly to Jump directly to the main content Jump directly to the search Open main navigation Close main navigation Main menu About Investment Fields Team Portfolio Contact us Ventures we believe in We invest in both visionary startups and specialized venture funds, and collaborate closely with our portfolio companies. These are some of the pioneering teams and funds we are proud to partner with. Our startup portfolio Cellvie The US-based biotech company Cellvie focuses on therapeutic mitochondria transplantation, a novel treatment approach aimed at … lves for a variety of uses in personal and industrial context. salvalco.com Our fund partners NCA As founding member and limited partner of the Next Commerce Accelerator (NCA) we are especially proud of this innovation network, that is a startup acceleration program and an investment fund at the same time. nca.vc YZR YZR accelerates Health Tech disruption in Europe and supports European health tech founders on their way to becoming global technology leaders. yzr-capital.com E … ogy leaders. yzr-capital.com Emerald Emerald's Sustainable Packaging Innovation Fund seeks investments in sectors across all stages of the circular economy ranging from raw materials to plastics recycling. emerald.vc Revent The Berlin-based impact Fund Revent aims to build the leading European platform for purpose-driven founders and to address key issues for society and the planet. revent.vc Beiersdorfstraße 1-9 D-20245 Hamburg Germany Tel.: +49 (0) 40 - 4909 0 vc@beiersdorf
Breakthrough in mitochondria therapy: CSEM and cellvie automate isolation process for clinical use Home Science About us Careers News Contact News 03.09.2025 Breakthrough in mitochondria therapy: CSEM and cellvie automate isolation process for clinical use cellvie, a pioneer in leveraging the therapeutic potential of mitochondria—the energy-producing structures within cells—is developing a novel treatment for ischemia-reperfusion injury, which could benefit > 3 million patients in Europe and the USA every year. A main bottleneck for clinical translation and particularly scaling, … gether with the Swiss technology innovation center CSEM, received an Innosuisse grant of more than CHF 700,000 to advance cellvie's mitochondrial isolation process with the goal of enabling scalable, consistent, and cost-effective manufacturing of its therapy. Enabling GMP-Grade Mitochondria Isolation The original mitochondria isolation protocol conceived by cellvie’s co-founder Dr. McCully required several manual steps and open manipulation, which could introduc
Who Attended Targeting Mitochondria 2023? - World Mitochondria Society The Future of Medicine will come through Mitochondria We are excited to invite you to the 17th World Mitochondria Scoiety's Annual Meeting, happening from October 21–23, 2026, in Berlin. This annual event brings together top experts in mitochondrial research and medicine to share new discoveries and ideas in mitochondrial therapy, gene treatment, and mitochondrial transplantation. READ MORE ... Who Attended Targeting Mitochondria 2023? Industries Stealth Therapeutics (Sponsor) Mitotech (Sponsor) Anklam Extrakt GmbH Cellvie … on at the 17th World Congress on Targeting Mitochondria... Read more Best Image Award 2025 Winners Announced We are thrilled to reveal the three winners of the Best Image in Mitochondria Research 2025! ... Read more Mitochondria & Organelle Crosstalk - Rethinking Organelle Crosstalk: Mitochondrial-Derived Vesicles in Peroxisome Biogenesis Presented by Dr. Ayumu Sugiura At the heart of cellular metabolism, mitochondria and peroxisomes play tightly interconnected rol … niversity of Groningen, Netherlands, for receiving the Best Poster Presentation Award at the 15th... Read more Gallbladder Mitochondrial Function as a Predictor of Liver Transplantation Outcomes Wins WMS Best Poster (2) The World Mitochondria Society is excited to announce that Danielius Umbrasas from the Lithuanian University of Health Sci... Read more Nominations for Best Mitochondria Image 2024 1. Never Tear Us Apart By Una Rastovic, The Roger Willi
Cellvie raises USD 5 million to advance kidney transplant therapy | Startupticker.ch posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … by neurodegenerative disorders.” Led by SV Health Investors’ Dementia Discovery Fund and joined by British Business Bank, M Ventures, Novartis Venture Fund, and others, the funding will propel NRG’s lead candidate NRG5051 into clinical trials for ALS/MND and Parkinson’s disease starting in early 2026. Read more https://lnkd.in/eaGpkKaM #therapeutics 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Kyle LaHucik 9mo Report this post ArsenalBio, a … ajor scientific discovery, which has enabled a new composition of matter patent application for the (E,E)-bisantrene compound. Dr Tillett explains why composition of matter patents are considered the gold standard in biotech IP, critical for securing future licensing and acquisition interest from major pharma players. A big thank you to Tylah Tully and the team at Stockhead for the coverage. Click the link in the comments to watch the full interview. #Biotech #CardioOncology … neuroscience biotech company led Co-founder & CEO Neil Miller & CFO/Coo Grant Hawthorne . Developing mitochondria-targeted small molecule therapeutics for neurodegenerative diseases. The company’s proprietary technology focuses on inhibiting the mitochondrial permeability transition pore (mPTP) to protect neurons from cell death - a key factor in diseases like Parkinson’s disease, ALS (MND), and other chronic neurological conditions. 💰 Total Funding – NRG Therapeutic … nnounced September 2025). 📈 Investors: SV Health Investors' Dementia Discovery Fund (DDF) , The Michael J. Fox Foundation for Parkinson's Research , TARGET ALS FOUNDATION, INC . Omega Funds , Innovate UK , Parkinson's UK 🚀 The new capital will be used to: 1️⃣ Advance NRG-001 into first-in-human clinical trials for Parkinson’s disease 2️⃣ Delive
cellvie Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners Turboc … o see more Corporate Venture Germany 00/00/0000 00/00/0000 Science Breakthrough Award Subscribe to see more Business Plan Competition Germany 00/00/0000 00/00/0000 MedTech Innovator Subscribe to see more Incubator/Accelerator California First funding 1/25/2021 00/00/0000 00/00/0000 00/00/0000 00/00/0000 Last Funding 9/9/2025 00/00/0000 00/00/0000 00/00/0000 00/00/0000 Investor Kizoo Technology Ventures Taiho Ventures Beiersdorf Venture Capital Science Breakthrough Award MedTe
Rejuvenation Startup Summit 2024 announces first set of speakers - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Rejuvenation Startup Summit 2024 announces first set of speakers November 8, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Join the largest in-person gathering of CEOs from the worldwide Rejuvenation & Longevity biotech sector Join the largest in-person gathering of CEOs from the worldwide Rejuvenation &am … e Healthy Longevity Clinic and Managing Partner of LongevityTech.fund Brian Kennedy, Professor at the National University of Singapore Eric Verdin, CEO and president of the Buck Institute for Research on Aging Investors on stage: Jens Eckstein, Investment Partner at Hevolution Alex Colville, Co-Founder, General Partner at Age1 Jan Adams, Partner at Apollo Health Ventures Sergey Jakimov, Managing Partner at LongeVC Marc P. Bernegger, Founding Partner … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Harvard spin-off CELLVIE closes $5M seed round for therapeutic mitochondria transfer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Ca … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Harvard spin-off CELLVIE closes $5M seed round for therapeutic mitochondria transfer January 25, 2021 | 4 min read Twitter LinkedIn Facebook Email Print cellvie Inc., the leader in Therapeutic Mitochondria Transfer (TMT) and a Harvard University spin-off, closes a $5M round to advance its product pipeline, … spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation. $5M financing round led by Kizoo Technology Capital Fresh capital to be employed for productization, to prepare a clinical trial in organ transplantation and to expand cellvie’s pipeline into rejuvenation therapies Promising initial clinical data generated at Boston Children’s Hospital to be published in the Journal of Thoracic and Cardiovascular Surgery Zurich/Switzer … spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation. Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinso … The investment will enable us to pursue the platform broadly, including a first application in aging, where the need for mitochondria-recovery is particularly dear.” To date, cellvie focused primarily on ischemia-reperfusion injury (IRI), one of the world’s leading causes of death. IRI manifests itself whenever the blood flow to a part of the bod
Harvard spin-off CELLVIE raises $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Dev … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Harvard spin-off CELLVIE raises $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality February 6, 2023 | 2 min read Twitter LinkedIn Facebook Email Print cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT), an … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mitochondria Transplantation Therapy – It’s Farther Along Than You Think | RoosterBio Skip to content Menu Site Navigation Our Technology Foundation for Multiple Therapeutics Powerful Technology Built-In Manufacturing Process Products Human Primary Cells Bone Marrow-derived hMSCs Adipose-derived hMSCs Umbilical Cord-derived hMSCs Neonatal Dermal Fibroblasts QuickShip™ Cell Banks Cell & Exosome Media hMSC Expansion Media hMSC Bioreactor Feed Exosome Media QuickShip™ MSC & Exosome Media cGMP CliniControl™ Products Human Primary Cells hMSC Expansion Media hMSC Bioreactor Feed Exosome Medi … son Syndrome Biological: CD34+ cells enriched with MNV-BLD NCT03639506 Clinical Application of Autologous Mitochondria Transplantation for Improving Oocyte Quality. 21-Aug-18 Not Applicable Sun Yat-sen University Unknown status Repetition Failure Procedure: autologous mitochondria transplantation|Combination Product: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|Drug: intracytoplasmic sperm injec
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Die neue Mitochondrien-Therapi ... – staYoung - Der Longevity-Podcast – Apple Podcasts Suchen Startseite Neu Top-Charts Suchen 19. April 2024 39 Min. Die neue Mitochondrien-Therapie: Dr. Alexander Schueller über die neuen Chancen der Medizintechnik staYoung - Der Longevity-Podcast Wiedergeben Nutze diesen Link https://link.stayoung.de/ForYou_Spot und spare mit dem Code: Ruge15 15% Rabatt auf Deine erste Bestellung bei for you ehealth In diesem Podcast spreche ich mit Dr. Alexander Schueller Zusammen mit Wissenschaftlern der Harvard University gründete er das StartUp CellVie, welches die Mit
Alexander Schueller & Tobias Reichmuth - cellvie & maximon | The Future Of Human Aging Digitec Galaxus: Vom 25m²-Büro zum grössten Onlineshop der Schweiz 🎥 Learn Podcast Candid conversations Free Startup Masterclasses Masterclasses by-founders, for-founders Swiss Startup Mafia Map Check out the intricate web of connections between Swiss startups Subscribe to our Newsletter Get updates and access to exclusive startup content Engage Community & Events Connect with Swiss founders Scaleup Circle Operator-led community Syndicate Invest in startups From 5'000 swiss francs Get sta … ffer benefits such as a sabbatical semester every 10 years, plus an educational stipend, so that every 10 years you may reinvent your career if you so choose. Memorable quotes: "The ideal human future is one in which you are free from disease and have a strong purpose up until the very end of your life." "Our goal is for people to die as late as possible, with a body as young as possible." If you would like to listen to more episodes about healthtech, ch … ng Masterclass B2B Sales Masterclass Swisspreneur Blog Community Startup Events Apply to Join the Slack Community Syndicate Startup investments with Swisspreneur Investors: Sign Up for Deals Startups: Apply to Pitch Investment Portfolio About Swisspreneur Team Contact Us Media Kit Subscribe to our Newsletter © Swisspreneur 2024. All rights reserved · Privacy Policy · Contact us Subscribe to our newsletter Get updates and access to exclusive content. We’ll never share your ema
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Episode – Page 2 – MedTech Chat Skip to content MedTech Chat Discover tomorrow’s medical tools and technology from entrepreneurs, designers, engineers, investors, insights professionals and executives. How will future MedTech help patients and the healthcare providers serving them? Menu Home Blog Posts Podcasts About Me Archives: Episode Michael Cima Drug and Medical Device Development Professor Cima discusses his executive course at MIT through Emeritus. The 8-week course is a strategic approach to drug and medical device development. It is designed for individuals and companies t
Do you think ageing can be reversed? Here are 12 longevity startups to watch | Sifted Analysis October 10, 2022 Do you think ageing can be reversed? Here are 12 longevity startups to watch The quest to slow down ageing — and have healthier and longer lives — is ongoing. And it’s not just about living to 120 Mimi Billing 8 min read Share Nuritas founder and CEO Nora Khaldi The quest to slow down ageing — and have healthier and longer lives — is ongoing. And it’s not just about living to 120. Some scientific research suggests that in years to come, we will have therapeutics that will help us for … vity VC Apollo Health Ventures, Swiss Korify Capital and US-based Longevitytech Fund Senisca (UK) Founded: 2020 by Lorna Harries, Ben Lee and Kirsty Semple (spinout from University of Exeter) As we age, more and more of our cells stop dividing and become senescent, or "zombie" cells. These cells don’t die but are major contributors to age-related illnesses such as cancer, dementia and cardiovascular disease. Senisca’s treatment rejuvenates these cells. The spinout is developi … ue, UK-based Grosvenor's Wheatsheaf Group, and the European Circular Bioeconomy Fund among others. Biolytica (Switzerland) Founded: 2021 by Rob Konrad Maciejewski and James Raaff There are a lot of companies selling longevity supplements, checking your blood markers and biomarkers and even looking at how your DNA may be working for or against you when it comes to certain age-related diseases. But how do you put all that information together into a longevity package that is ri … ovable and how startups can partner with the tech giant News EIF launches €15bn fund of funds to back 100 growth-stage VCs Mimi Billing Mimi Billing is Sifted's Europe editor, based in Stockholm. She covers the Nordics and can be found on X and LinkedIn # Healthtech # Venture capital # Investor survey Sifted Daily newsletter Weekdays Stay one step ahead with news and experts analysis on what’s happening across startup Europe. Sign up for free Recommended Health unicorn Alan r
#mitochondria #mitochondria_transfer | Olga Borysova LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy ,
MITO2i x JLabs Industry Event | Mito2i Search for: BECOME A MEMBER ABOUT US Who We Are Scientific Leadership Team Executive Leadership Team Partners EDUCATION MITO Podcasts MITO Voice MITO Stories Additional Resources RESEARCH Research Areas MITO TRANSPLANT Publications Funded Projects MITO Innovation Scholars 2025 Scholars 2024 Scholars 2023 Scholars 2022 Scholars 2021 Scholars Post Doctoral Fellows Research Opportunities Graduate student scholarship 2025 PhD Exchange Program IPTN Therapeutic Nutrition Course Award Announcement- NFRFT MITO TRANSPLANT EVENTS Upcoming Events Event Archive NEWS … ellvie is targeting ischemia-reperfusion injury as its technology’s first application. BHARAT SRINIVASA CO-FOUNDER AND PRINCIPAL, AMPLITUDE VENTURES Bharat Srinivasa brings a wealth of experience from his previous role on the investment team at the BDC Healthcare Fund. Before his venture into investment, he honed his expertise in healthcare consulting, specializing in areas such as forecasting, commercial analytics, and business intelligence for pharmaceutical companies
cellvie secures USD 5 million for mitochondria-based therapeutics | Venturelab posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … ks, stroke, and complex surgeries. 💰 In addition, a CHF 1.5 million Innosuisse grant is fueling their pioneering mitochondria-enabled gene delivery platform, further expanding therapeutic possibilities. Congratulations to the team for this impressive milestone! 👏 #SwissStartups #VLeadersBiotech #Biotech #Innovation #Entrepreneurship 34 1 Comment Like Comment Share Copy LinkedIn Facebook X cellvie 9mo Report this comment Thanks a lot for featuring our round of funding and fo … ristian and his team, with support from visionary investors at Novartis Venture Fund and OrbiMed realized that this wasn’t just about #fibrosis . The same approach could unlock treatments for #oncology , monogenic blood disorders, and even autoimmune diseases. The insight? 👉 Transition from a product to a platform. 👉 Build something that could serve multiple therapeutic frontiers, not just one. But with big opportunities come big debates. Investors pushed for oncology the f
Science - cellvie Inc. Home Science About us Careers News Contact Science Reinvigorating the cell energy metabolism Mitochondria dysfunction has been tied to a host of medical conditions, including heart disease, stroke, diabetes, Parkinson's and Alzheimer's. But mitochondria have, for the most part, eluded treatment. This compelled Dr. McCully and his team to think in new ways. Why Mitochondria Therapy? When Mitochondria, a form of bacteria at the time, merged with what was a simple cell-organism, the ensuing symbiosis gave rise to complex life. Today, mitochondria are present in almost every … ibute to the cells' energy metabolism. Ischemia Reperfusion Injury In the first application for unmodified mitochondria, we seek to treat ischemia-reperfusion injury, with kidney transplantation as the first indication. Ischemia-reperfusion injury is the world’s number one killer. It is ubiquitous - arising whenever blood flow is interrupted and subsequently reintroduced. The damage unfolds in two waves. The first comes with ischemia itself: deprived of oxygen, cells de … antation as its first indication, with plans to expand from there. First application: Kidney transplantation With 100,000 patients on the waiting list for a kidney and 12 of them dying each day, the need to improve access to and performance of these grafts is dire. Ischemia-reperfusion injury (IRI) is a key constraint on donor organ availability and a key driver of post-transplant performance, and longevity: the fear of ischemic damage limits allowable transport times … bullosa as its first indication, with plans to expand from there. First Application: Epidermolysis bullosa Epidermolysis bullosa (EB) is a rare and devastating genetic disease. Patients – many of them children – suffer from fragile skin, chronic wounds, pain, infections, and complications affecting internal tissues. We focus on the most severe form, Dystrophic EB (DEB), in which a deficiency in the COL7A1 gene leaves patients without functional Type VII Co
Therapeutic Mitochondria Transfer (TMT) Cellvie Inc. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Accelerate AI in UK DaltonTx Launches … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
cellvie AG - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membership Optio
Home - cellvie Inc. Home Science About us Careers News Contact LEVERAGING THE POWER OF EVOLUTION At cellvie, we are pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism. We are deriving medicines from cells, leveraging one of the cornerstones of evolution: mitochondria. TO SAVE AND RESTORE "Perhaps no structure is so intimately and simultaneously connected to both the energy of youth and the decline of the old" — (Sun et al.; 2020) Mitochondria are the powerhouses of the cell. cellvie is employing Therapeutic Mitochondria … igorate the cell energy metabolism when the mitochondria are failing. The first application will be in ischemia-reperfusion injury, the world's number 1 killer. MITOCHONDRIA ARE INTIMATELY TIED TO THE ORIGIN OF COMPLEX LIFE Mitochondria are membrane-bound cell organelles that generate most of the energy needed to power the cell's biochemical reactions. In a process referred to as symbiogenesis, mitochondria are said to have merged with a simple cellular organism, giving rise … jury cellvie is targeting ischemia-reperfusion injury as its technology's first application. Ischemia-Reperfusion is a ubiquitous challenge, arising whenever blood flow is interrupted and subsequently re-introduced. Medical conditions giving rise to ischemia-reperfusion injury are heart attacks, stroke, long surgical procedures and organ transplantation. The first indication will be in kidney transplantation. With 12 patients dying each day waiting for a kidney, the need is p … sion injury, the team at cellvie is particularly interested in the technology's application to slow or reverse degenerative processes of aging linked to the mitochondria. GENETIC DISEASES Leveraging their efficient cellular uptake and endosomal escape capabilities, cellvie is employing mitochondria as a novel vector to target genetic diseases. What makes mitochondria unique is their large payload capacity, distinct distribution pattern, and superior safety profile. The first … capacity, distinct distribution pattern, and superior safety profile. The first application will be in Epidermolysis Bullosa, a rare and devastating genetic disease. Patients - many of them children - suffer from fragile skin, chronic wounds, pain, infections, and complications affecting internal tissues. For many, the origin lies in a deficiency
cellvie secures $5 Million in fresh capital from existing and new investors - MedTech Innovator Open Menu Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager MedTech Innovator Fellows Program Join the Ecosystem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Heart & Brain Health Accelerator Track MedTech Innovator Plastic Surgery Accelerator … 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Company Videos Portfolio Companies MEMBER News Press Releases Cohort & Partner News Ecosystem Job Opportunities Log in Apply Apply to MedTech Innovator US Apply to MedTech Innovator APAC Apply to BioTools Innovator About About MedTech Innovator MedTech Industry Strategic Interest Areas Partners Careers and Fellowships Program Manager MedTech Innovato … tem Ecosystem Job Opportunities Media Kit Contact Us US Program Information and Application Program FAQ Specialty Tracks MedTech Innovator Heart & Brain Health Accelerator Track MedTech Innovator Plastic Surgery Accelerator Track Webinars 2026 Cohort Companies Company Videos Alumni Portfolio Asia Pacific APAC Accelerator US Market Access Webinars 2025 Cohort Companies Company Videos Alumni Portfolio BioTools Information and Application Webinars 2025 Cohort Companies Comp … More Share Post: Koya Medical Receives “Building Tomorrow Together” Award from Dallas Regional Chamber CHO Plus Obtains U.S. Patent for Improved Production of Proteins Using Engineered Yeast Cells ABOUT MEDTECH INNOVATOR MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Our mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. Terms & Con … e improving human health Donate Applications for the 2026 Accelerator are Open! Deadline: December 1, 2025 APPLY NOW ×
cellvie and CSEM Automate Mitochondrial Isolation to Enable Breakthrough Therapies - BioAlps Skip to content Bio Alps FIND A HEALTH VALLEY ACTOR Menu Search News BioAlps news BioAlps 20 years Events About Mission Organization Members and Strategic Partners BioAlps Awards Media Center News Events BioAlps events Life science events About Mission Organisation Executive Committee BioAlps Team -- Members and Strategic Partners BioAlps Awards Media Centre Publication -- --> BioAlps Event Formats Business Opportunities Community Membership Registration The BioAlps Community Business opportunities Com … with the Swiss technology innovation center CSEM and supported by an Innosuisse grant of over CHF 700,000, the teams redesigned the process. Together, they developed a closed, fully automated system for mitochondrial isolation in a single streamlined workflow. “A robust and scalable system is essential to ensure the bioenergetic functionality and safety of mitochondria and to bring revolutionary therapies to clinics,” said Charlotte Fonta, Senior R&D Engineer at CSEM. Thi
cellvie | MedTech Innovator Job Board MedTech Innovator Portfolio Company Careers Search jobs Explore companies Join talent network Talent My job alerts cellvie cellvie.bio Locations Houston, TX, USA · Switzerland · Zürich, Switzerland industry Biotechnology · Biotechnology Research · Life Science · Therapeutics Size 1 - 10 employees Stage Seed founded in 2018 Socials LinkedIn Crunchbase Twitter About Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Mitochondria are at the heart of complex life's origin. Likely a b
cellvie raises $5M for mitochondria therapy for ischemia-reperfusion-injury | Dr. Alexander Schueller posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Contin … financing was led by DYDX Capital with participation from new investors Gravity Fund and NVNG Investment Advisors, LLC and existing investors Great Oaks Venture Capital , WARF Ventures, among others. Read the release for more: https://lnkd.in/guKzprnN Learn more at www.immutotherapeutics.com #drugdiscovery #oncology #cancer #structuralsurfaceomics #targetdiscovery #ADCs #biotech #financing …more Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration … argets in cancer. We’re pleased to welcome new investors DYDX Capital , Gravity Fund , and NVNG Investment Advisors, LLC to the team, and to deepen our partnership with the investors who have supported us from day one, including Great Oaks Venture Capital , Wisconsin Alumni Research Foundation (WARF) Ventures, and others. Over the last few years, our team has been working relentlessly to build cutting-edge platforms with unparalleled capabilities to uncover novel, disease-spe … financing was led by DYDX Capital with participation from new investors Gravity Fund and NVNG Investment Advisors, LLC and existing investors Great Oaks Venture Capital , WARF Ventures, among others. Read the release for more: https://lnkd.in/guKzprnN Learn more at www.immutotherapeutics.com #drugdiscovery #oncology #cancer #structuralsurfaceomics #targetdiscovery #ADCs #biotech #financing Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Un … els is thrilled to join up with Spencer M. of DYDX Capital , Adam G. of Gravity Fund , and continue the journey with Greg Keenan , Joshua J. Carson , Katie Rice , and Mike Partsch at Wisconsin Alumni Research Foundation (WARF) Ventures, Great Oaks Venture Capital , Brad Bodden Wisconsin Investment Partners , among others. Collectively, we're exci
Jobs at cellvie AG | JOIN cellvie AG 1-10 employees Biotechnology Research Spun out from Harvard, cellvie is a venture-backed biotechnology start-up striving to bring about mitochondria as a new treatment modality. Website Open positions About us Open positions Department All departments Location All locations No available jobs We don't have any open positions at the moment About us Spun out from Harvard, cellvie is a venture-backed biotechnology start-up striving to bring about mitochondria as a new treatment modality. WE HIRE WITH JOIN Terms & conditions Privacy policy Report issue
CELLVIE closes $5M Seed Round led by Kizoo Technology Home Science About us Careers News Contact News 28.01.2021 CELLVIE closes $5M Seed Round led by Kizoo Technology Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer $5M financing round led by Kizoo Technology Capital Fresh capital to be employed for productization, to prepare a clinical trial in organ transplantation and to expand cellvie's pipeline into rejuvenation therapies Promising initial clinical data generated at Boston Children's Hospital to be published in the Jo … spin-off closes a $5M round to advance its product pipeline, including a first application in rejuvenation. Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinso … The investment will enable us to pursue the platform broadly, including a first application in aging, where the need for mitochondria-recovery is particularly dear." To date, cellvie focused primarily on ischemia-reperfusion injury (IRI), one of the world's leading causes of death. IRI manifests itself whenever the blood flow to a part of the body is interrupted and subsequently reintroduced. Well-known medical conditions include heart attacks, strokes, and organ transplantat … ning research on the root causes of aging into therapies and services for human application. Investments include FoxBio, Turn.bio, AgeX, Elevian, Oisin Biotechnologies, LIfT BioSiences, MAIA Biotechnology, and others. Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conferenc
cellvie’s co-founder interviewed by and featured in European Biotechnology Home Science About us Careers News Contact News 29.05.2024 cellvie’s co-founder interviewed by and featured in European Biotechnology EuroBiotech _Mitochondria are not part of the standard repertoire of research, let alone clinical practice. Are the systems for dealing with these cell organelles sufficiently developed? Alexander Schueller _Mitochondria remain somewhat elusive, given that most laboratory technologies available today were designed for research on cells – which are often more than 1000-fold larger th … ise. Most notably and repeatedly, in ischemia-reperfusion injury, which was the application wherein my co-founder, Dr. McCully, pioneered the field. Ischemia-reperfusion injury arises whenever the flow of blood is interrupted and subsequently re-introduced. Medical conditions include heart attacks, organ transplantations, strokes, or long surgical procedures. There are hence millions of patients that stand to benefit each year. Recently, a group in the US, in collaboration wi … nerally speaking, the average investor, especially in Europe, does not have the fund size or mandate to fund the emergence of a new field of medicine. EuroBiotech _Buzzwords such as longevity are not enough to open the check books? Schueller _While the attraction of longevity is real, buzzwords won’t do with sophisticated investors. I would also say that while interest in longevity has risen exponentially in the general population and with certain groups of highl … insufficient marketing within the longevity community? Schueller _The potential application in aging-related degeneration has gotten us off the ground. It has been the shared vision of Michael Greve and cellvie. But as we are eying a substantial Series A, we must look towards more timely and tangible areas of development. Such as in organ transplantation. EuroBiotech _Would you characterise Europe’s VC landscape as more risk averse and hence consider the US as mo … we are now aiming for a Series A financing of US$30-40m. As a lead investor, a fund would need to commit US$10-15m in such a round. For one, there are not that many funds in Europe large enough to write checks of this size. And within those funds that can, there will be only a limited number of investment allocations reserved for truly novel con
Careers - cellvie Inc. Home Science About us Careers News Contact Careers Together we may succeed To realize the therapeutic potential of mitochondria, to bring about a new treatment modality, it takes a team with wit, dedication and grid. We are looking for entrepreneurial team players who are passionate about making a difference and ready to take on the challenges such an undertaking comes with. We currently have no open roles but are always looking for talented members of the team, please get in touch via [email protected] Current Openings What's new? Explore Copyright © 2026 cellvie In
CELLVIE announces strengthening of leadership team with hiring of CSO & COO. Home Science About us Careers News Contact News 28.06.2023 CELLVIE announces strengthening of leadership team with hiring of CSO & COO. cellvie, a leader in Therapeutic Mitochondria Transplantation (TMT), is spearheading a ground-breaking treatment modality that harnesses the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation, an innovative approach for rescuing and amplifying mitochondria function, was developed by Dr. James McCully at Harvard Medical Scho
Cellvie | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Cellvie Cellvie is a pioneering biotechnology company developing medicines from cells, with a focus on leveraging the therapeutic potential of mitochondria. Founded in 2018 and headquartered in Zurich, Switzerland, the company is advancing a novel treatment modality called Therapeutic Mitochondria Transplantation, aimed at addressing conditions such as ischemia-reperfusion injury, aging, and other diseases related to mitochondrial dysfunction. Cellvie's mission is … essing Show More (7) Show less News & Updates cellvie AG secures Innosuisse grant with CSEM to advance their mitochondria-based therapy platform cellvie, together with CSEM, received an Innosuisse grant to develop scalable mitochondrial isolation processes for therapy manufacturing. cellvie’s co-founder interviewed by and featured in European Biotechnology Alexander Schueller discussed the regulation, potential, and applications of mitochondria transplantation in aging an … ndria as a treatment for aging-related degeneration. De Vigier Entrepreneurship Award 2021 CEO Dr. Alexander Schueller received the prestigious De Vigier Award for innovation and societal value. MedTech Innovator Value Award 2020 cellvie was selected as a finalist and winner of the Value Award for its innovative mitochondria therapy. Falling Walls Summit Cluster Winner in Health Solutions 2022 Recognition for innovative health solutions at a major international summit. View A
cellvie Secures Innosuisse Funding to Advance Mitochondrial Gene Therapy Home Science About us Careers News Contact News 24.10.2024 cellvie Secures Innosuisse Funding to Advance Mitochondrial Gene Therapy cellvie AG is thrilled to announce that it has been awarded a grant under the highly competitive Swiss Innovation Project (SIP) scheme of Innosuisse. Known for supporting groundbreaking Swiss technologies, the Innosuisse SIP initiative funds innovative and impactful projects, which demonstrate technical and scientific excellence, along with strong economic potential. The funded … otal budget of CHF 2.1 million, with 70% of the costs covered by the Innosuisse grant. This funding will allow cellvie to advance its pipeline to a point that venture investments or strategic collaborations for mitochondria-enabled gene therapy are within reach. "This grant underlines the platform potential of mitochondria and will enable the accelerated development of mitochondria-enabled gene therapy, in addition to our ongoing work in ischemia-reperfusion injury
cellvie closes $5.5M new funding Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector Approaches Antibody … ch podcast 19: Bone Health Technologies, Immutep, TAU Systems Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA €5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic 3T Biosciences launches with $40M financing InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics Latest Articles Roche, a company built on oncology and diagnostics reinventing its pipeline Bronchiectasis treatment after brenso
News – cellvie Inc. Home Science About us Careers News Contact News Advancing medicine, step by step Learn of and follow our journey to bring about Therapeutic Mitochondria Transplantation as a new treatment modality News & Publications News 21.04.2026 cellvie featured in Gen Suisse: advancing gene therapy through mitochondrial innovation cellvie has been featured in an article by Gen Suisse, highlighting its pioneering approach to leveraging mitochondria as a novel platform for next-generation therapies. Read more News 26.02.2026 cellvie Presents at CEOT 2026 It was a great pleasure for c … rial Gene Therapy cellvie AG is thrilled to announce that it has been awarded a grant under the highly competitive Swiss Innovation Project (SIP) scheme of Innosuisse. The funded project will further establish and advance the use of mitochondria as delivery vectors for gene therapy payloads, a novel approach that could open new frontiers in gene therapy. Read more News 29.05.2024 cellvie’s co-founder interviewed by and featured in European Biotechnology BEING EARLY - There is … g related degeneration. Read more News 14.11.2023 cellvie AG secures Innosuisse grant with CSEM to advance their mitochondria-based therapy platform cellvie, a pioneer in leveraging the therapeutic potential of mitochondria, together with CSEM, was selected as recipient of an Innosuisse grant with a total project value of more than CHF 700,000. The project funded focuses on advancing cellvie's mitochondrial isolation process to enable the scalable, safe, and cost-effective ma
cellvie AG secures Innosuisse grant with CSEM to advance their mitochondria-based therapy platform Home Science About us Careers News Contact News 14.11.2023 cellvie AG secures Innosuisse grant with CSEM to advance their mitochondria-based therapy platform cellvie, a pioneer in leveraging the therapeutic potential of mitochondria, together with CSEM, was selected as recipient of an Innosuisse grant with a total project value of more than CHF 700,000. The project funded focuses on advancing cellvie's mitochondrial isolation process to enable the scalable, safe, and cost-effective manufacturing … to partner with CSEM, an expert in the field of automation, on this Innosuisse grant,” commented Dr. Alexander Schueller, founder and CEO of cellvie. “The grant is a recognition of our team's unwavering commitment to and progress in developing mitochondria as a new treatment modality to help patients in dear need.” The technology's first application will be in ischemia-reperfusion injury, a condition arising in patients receiving an organ transplant, or tho … ochondria, the development of which will be accelerated through this Innosuisse grant. Contact: Dr. Alexander Schueller, CEO tel.: +41-44 591 89 21 email: [email protected] About cellvie Inc. and cellvie AG (cellvie) Founded in the US and operationally headquartered in Zurich in Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. McCully, Schueller, del Nido and Emani in 2018.
CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation Home Science About us Careers News Contact News 06.02.2023 CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation Harvard spin-off CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality. $5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital Gm
About Us - cellvie Inc. Home Science About us Careers News Contact About us Committed to advance medicine At cellvie, we believe in the power of cell-derived medicines. We are dedicated to bring about nothing short of a new treatment modality, to safe and improve the lives of patients in need. We take joy from and pride in facing the challenge of advancing medicine. cellvie's greatest asset A medicinal invention is only as meaningful as the products it spurs that reach patients in need. To turn Therapeutic Mitochondria Transplantation from an approach to a platform of products takes a team of … shape the company's priorities and support in their realization. Join our team Apply now Copyright © 2026 cellvie Inc. - All Rights Reserved. Home Science About us Careers News Contact Privacy policy Dr. Alex Schueller × Alex is a repeat-entrepreneur in the life sciences, having co-founded, built and successfully exited Adhesys Medical, after starting his professional career at The Boston Consulting Group. Alex had known Pedro from his first venture and when he wa … am Emani, Pedro and Jim embarked on taking the technology to its first clinical application. Dr. Sitaram Emani × Ram is a highly accomplished cardiothoracic pediatric surgeon, focusing on complex repairs at Boston Children’s Hospital. He has a strong track-record in translating novel therapies into clinical practice, particularly in the cell- and gene therapy space. When Ram became aware of therapeutic mitochondria transplantation (TMT) through his work with Jim a
cellvie secures $5 Million in fresh capital from existing and new investors Home Science About us Careers News Contact News 09.09.2025 cellvie secures $5 Million in fresh capital from existing and new investors Zurich, Switzerland – September 9th, 2025 – cellvie, a company pioneering therapeutics based on mitochondria, today announced the closing of a $5 million funding round, with participation from both existing and new investors. The round was led by Taiho Ventures, with major contributions from Kizoo Technology Capital, an existing investor, and Beiersdorf Venture Capital. The … enefit from the therapy. In parallel, supported by a CHF 1.5 million Innosuisse grant, the company is developing a mitochondria-enabled gene delivery platform that leverages the organelle’s unique biodistribution and efficient cellular uptake. With this financing, cellvie is accelerating towards clinical translation of its lead asset. To support the next phase of development - including the completion of a Phase I/IIa clinical trial in kidney transplantation - cellvie i … team is focusing on ischemia-reperfusion injury as the technology’s first application - a thus far intractable disease pathology and leading cause of death arising in heart attacks, stroke, or organ transplantation. cellvie believes in the platform potential of mitochondria honing a pipeline of applications in the fields of cell and gene therapy and longevity. About Taiho Ventures Taiho Ventures, LLC is a strategic corporate venture arm of Taiho Pharmaceutical Co., Ltd.